Figure 5.
SRI31277 is effective in the immunocompetent 5TGM1 model. 5TGM1 cells engineered to stably expressed luciferase (1 × 106 cells) were injected into the lateral tail veins of syngenic C57BL/KaLwRij mice. Treatment with either saline or 30 mg/kg per day SRI31277 delivered by osmotic pump was initiated on day 9 after tumor cell injection and continued for 27 days (n = 10 per group). Tumor burden was measured on day 27 by evaluation of serum mouse IgG2b by enzyme-linked immunosorbent assay. Results are presented as means ± SEM [∗P < 0.05 (P = 0.039), unpaired t-test].